The role of brachytherapy in the treatment of glioblastoma multiforme

Barbarite, Eric; Sick, Justin; Berchmans, Emmanuel; Bregy, Amadé; Shah, Ashish H.; Elsayyad, Nagy; Komotar, Ricardo J.

doi:10.1007/s10143-016-0727-6

Cited by 49 publications

(41 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brachytherapy uses a radioactive substance located near or in the GBM tumor to deliver radiation therapy (Barbarite et al, 2017 ). BT enables to reduce side effects including damages to healthy tissues by concentrating the radiation beam in the regions where the tumor is located or is most the likely to recur.…”

Section: The Different Gbm Treatments Commercialized or Under Developmentioning

confidence: 99%

Glioblastoma Treatments: An Account of Recent Industrial Developments

Alphandéry

2018

Front. Pharmacol.

View full text Add to dashboard Cite

The different drugs and medical devices, which are commercialized or under industrial development for glioblastoma treatment, are reviewed. Their different modes of action are analyzed with a distinction being made between the effects of radiation, the targeting of specific parts of glioma cells, and immunotherapy. Most of them are still at a too early stage of development to firmly conclude about their efficacy. Optune, which triggers antitumor activity by blocking the mitosis of glioma cells under the application of an alternating electric field, seems to be the only recently developed therapy with some efficacy reported on a large number of GBM patients. The need for early GBM diagnosis is emphasized since it could enable the treatment of GBM tumors of small sizes, possibly easier to eradicate than larger tumors. Ways to improve clinical protocols by strengthening preclinical studies using of a broader range of different animal and tumor models are also underlined. Issues related with efficient drug delivery and crossing of blood brain barrier are discussed. Finally societal and economic aspects are described with a presentation of the orphan drug status that can accelerate the development of GBM therapies, patents protecting various GBM treatments, the different actors tackling GBM disease, the cost of GBM treatments, GBM market figures, and a financial analysis of the different companies involved in the development of GBM therapies.

show abstract

Section: The Different Gbm Treatments Commercialized or Under Developmentioning

confidence: 99%

Glioblastoma Treatments: An Account of Recent Industrial Developments

Alphandéry

2018

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Surgical resection followed by chemoradiation therapy has limited efficacy because of poor blood–brain barrier (BBB) penetration, intrinsic GBM resistance, and chemotherapeutic agent toxicity [1,3,4]. More aggressive radiotherapy improves patient outcomes and overall survival; however, the risk of radiation-related complications also increases [5]. Conventional chemotherapy with TMZ is used because it induces considerable DNA damage and triggers the apoptosis of glioma cells [6].…”

Section: Introductionmentioning

confidence: 99%

Application of Electric Cell-Substrate Impedance Sensing to Investigate the Cytotoxic Effects of Andrographolide on U-87 MG Glioblastoma Cell Migration and Apoptosis

Chiu

Buyandelger

Huang

2019

Sensors

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. In recent studies, the efficacy of suberoylanilide hydroxamic acid (SAHA) has been investigated for GBM. We explored the effects of two exploratory compounds, the histone deacetylase SAHA and the natural product andrographolide, on Uppsala 87 Malignant Glioma (U-87 MG) cell migration and viability in comparison with the clinically used therapeutic agent temozolomide (TMZ). We used the electric cell–substrate impedance sensing (ECIS) system to monitor the migration of U-87 MG cells after treatment with various concentrations of these compounds. Moreover, we used the Alamar blue assay and western blotting to observe the concentration-dependent changes in the viability and apoptosis of U-87 MG cells. Our results demonstrated that both SAHA and andrographolide (10–300 μM) significantly inhibited GBM cell migration in a concentration-dependent manner, and 10 μM SAHA and 56 μM andrographolide demonstrated remarkable inhibitory effects on U-87 MG migration. Western blotting indicated that compared with TMZ, both SAHA and andrographolide induced higher expression levels of apoptosis-related proteins, such as caspase-3, BAX, and PARP in U-87 MG cells. Furthermore, all three drugs downregulated the expression of the antiapoptotic protein Bcl-2. In conclusion, SAHA and andrographolide showed exceptional results in inhibiting cell migration and motility. The ECIS wound healing assay is a powerful technique to identify and screen potential therapeutic agents that can inhibit cancer cell migration.

show abstract

“…One of the main concerns about achieving a radical dose at brain tissue is the development of radionecrosis. This side effect has been the limiting burden for dose escalation, although brachytherapy dose-escalation reports suggested less severe complications rates than only EBRT-based approaches, with incidences ranging from 4 to 27%, [26,37]. The rate of radionecrosis in this analysis (25.1%) was seen to be higher than after standard of care (5-10%) [38] but lower than in the INTRAGO trial (33%) or after interstitial brachytherapy (~50%) [39].…”

Section: Discussionmentioning

confidence: 54%